Who is sponsoring NCT05129124?

NCT05129124 is sponsored by Bausch & Lomb Incorporated.

What drugs are being tested in NCT05129124?

Interventions in NCT05129124: kalifilcon A Daily Disposable Toric LD213001 Contact Lenses, Commercially available Ultra for Astigmatism Contact Lenses.

What condition does NCT05129124 study?

NCT05129124 studies Astigmatism.

Is NCT05129124 still recruiting?

NCT05129124 is currently completed. Last updated 10 July 2025.

Are results published for NCT05129124?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-07-10 · How we verify

NCT05129124

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact Lenses

Completed NA Results posted Last updated 10 July 2025

What this trial tests

NA trial testing kalifilcon A Daily Disposable Toric LD213001 Contact Lenses in Astigmatism in 30 participants. Completed in 13 January 2022.

Timeline

30 November 2021

Primary endpoint
13 January 2022

13 January 2022

Quick facts

Lead sponsor	Bausch & Lomb Incorporated
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	30 November 2021
Primary completion	13 January 2022
Estimated completion	13 January 2022
Sites	1 location across United States

Drugs / interventions tested

kalifilcon A Daily Disposable Toric LD213001 Contact Lenses
Commercially available Ultra for Astigmatism Contact Lenses

Conditions studied

Astigmatism — all drugs for Astigmatism →

Sponsor

Bausch & Lomb Incorporated — full company profile →

Who can join

18 and older, any sex, with Astigmatism. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Mean Absolute Primary Gaze Orientation at 3 Minutes for the Lenses Inserted at 90 Degrees Primary · 3 minutes

Primary gaze orientation is measured in degrees. Measurement Description: Primary gaze is when the patient is looking straight ahead. Orientation refers to how much the contact lens is rotated on the eye. Primary gaze orientation of the contact lens is measured in degrees at the slit-lamp (microscope) using a reticle (protractor). Lens orientation was measured in primary gaze in 5-degree increments. Negative values indicate the contact lens was rotated in the temporal direction. Positive values indicate the contact lens was rotated in the nasal direction. The greater the value (positive or neg

T01

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	1.3	± 3.92

C01

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	3.3	± 7.47

T02

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	2.0	± 4.47

C02

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	3.0	± 9.43

T03

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	1.7	± 3.79

C03

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	4.0	± 16.42

T04

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	4.2	± 13.90

C04

Group	Value	95% CI
All Participants Received Kalifilcon LD213001 ContactLenses and Ultra for Astigmatism Contact Lenses	1.3	± 2.60

Sponsor's own description

The objective is to evaluate the fit characteristics (primary gaze orientation, rotational recovery, and movement) of kalifilcon A daily disposable toric lenses as compared to commercially available Ultra for Astigmatism lenses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Astigmatism

Currently open trials in the same condition.

NCT07303920 — Wear Experience With Daily Disposable Contact Lenses for Astigmatism Over a Long-Wear Day · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07078799 — Wavefront-guided LASIK Surgery Compared to Ray Tracing-Guided LASIK Surgery · NA · recruiting
NCT07084844 — Patient Reported Outcomes With WaveLight Plus LASIK · recruiting
NCT07140653 — Arcuate Incisions With Light Adjustable Lens for Astigmatism Correction in Lens Surgery · Phase 4 · recruiting

Other Bausch & Lomb Incorporated trials

Trials by the same sponsor.

NCT07054606 — A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear · Phase 4 · completed
NCT06803654 — A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Rel · Phase 3 · completed
NCT06594185 — A Study to Evaluate Real World Outcomes of the enVista® Aspire (EA) and Aspire Toric (ETA) Intraocular Lens in Subjects · NA · completed
NCT06479148 — Clinical Evaluation of the Performance of the enVista® Aspire™ (EA) Lens · NA · terminated
NCT06333028 — A Study to Evaluate the enVista® Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05129124 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bausch & Lomb Incorporated
Last refreshed: 10 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05129124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing